← Leaderboards
Aftab A. Ansari
Emory University
$22,344,206
Attributed
$22,510,850
Total exposure
42
Grants
29
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.6M · FY2005–18$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$22,510,850 · 42
By mechanism
R01$17,315,597 · 6
P51$2,876,924 · 30
U19$1,923,258 · 4
R21$333,288 · 1
P30$61,783 · 1
Top collaborators
- Lyle Mckinnon2 shared
Others in their field
Top investigators on “Macaca Mulatta”
- Barton F Haynes · Duke University$291,595,855
- Peter Gordon Gillespie · Oregon Health And Science University$83,402,374
- Richard A Gibbs · Baylor College Of Medicine$82,928,769
- Dan H. Barouch · Fred Hutchinson Cancer Center$67,567,747
- David I Watkins · George Washington University$57,087,952
- Rama Rao Amara · Emory University$54,145,017
Research focus
Macaca MulattaInfectionGrantUnited States National Institutes Of HealthFundingResearch PersonnelBaseMonitorInstitutionImmune ResponseImmunologyViral Load ResultVirusCellsResourcesMonkeysIn VivoSourceImmuneChronicAcuteBloodAnimalsFunctional Disorder
Grant awards (77)
Pilot Project Core$151,320
U19 · FY2018 · AI · contact PI
Pilot Project Core$213,609
U19 · FY2017 · AI · contact PI
Gut Homing Cells in SIV infection$1,420,339
R01 · FY2016 · AI · contact PI
Integrin a4b7 as a predictor of HIV acquisition and pathogenesis$171,641
R21 · FY2016 · AI
Pilot Project Core$125,068
U19 · FY2016 · AI · contact PI
Gut Homing Cells in SIV infection$1,676,685
R01 · FY2015 · AI · contact PI
Integrin a4b7 as a predictor of HIV acquisition and pathogenesis$161,647
R21 · FY2015 · AI
Pilot Project Core$126,523
U19 · FY2015 · AI · contact PI
Gut Homing Cells in SIV infection$1,361,119
R01 · FY2014 · AI · contact PI
Pilot Project Core$152,445
U19 · FY2014 · AI · contact PI
Gut Homing Cells in SIV infection$1,262,680
R01 · FY2013 · AI · contact PI
Innate Immunity and SIV Infection$564,278
R01 · FY2013 · AI · contact PI
Pilot Projects$117,762
U19 · FY2013 · AI · contact PI
Innate Immunity and SIV Infection$2,143,058
R01 · FY2012 · AI · contact PI
Gut Homing Cells in SIV infection$1,323,534
R01 · FY2012 · AI · contact PI
Pilot Projects$123,098
U19 · FY2012 · AI · contact PI
Innate Immunity and SIV Infection$745,488
R01 · FY2011 · AI · contact PI
Pilot Projects$171,664
U19 · FY2011 · AI · contact PI
CD4 T CELL ACTIVATION IN SIV INFECTED DISEASE RESISTANT SOOTY MANGABEYS$74,294
P51 · FY2011 · RR · contact PI
INNATE IMMUNITY IN SIV INFECTION$59,500
P51 · FY2011 · RR · contact PI
THE ANTI-ALPHA-4/BETA-7 MONOCLONAL ANTIBODY PROJECT$59,500
P51 · FY2011 · RR · contact PI
ROLE OF VIRUS SPECIFIC IMMUNITY IN PRIMATE MODELS$59,500
P51 · FY2011 · RR · contact PI
Innate Immunity and SIV Infection$759,688
R01 · FY2010 · AI · contact PI
Pilot Projects$181,709
U19 · FY2010 · AI · contact PI
Innate Immunity and SIV Infection$155,000
R01 · FY2010 · AI · contact PI
CD4 T CELL ACTIVATION IN SIV INFECTED DISEASE RESISTANT SOOTY MANGABEYS$54,827
P51 · FY2010 · RR · contact PI
INNATE IMMUNITY IN SIV INFECTION$43,862
P51 · FY2010 · RR · contact PI
THE ANTI-ALPHA-4/BETA-7 MONOCLONAL ANTIBODY PROJECT$43,862
P51 · FY2010 · RR · contact PI
ROLE OF VIRUS SPECIFIC IMMUNITY IN PRIMATE MODELS$43,862
P51 · FY2010 · RR · contact PI
Innate Immunity and SIV Infection$720,585
R01 · FY2009 · AI · contact PI
MOLECULAR MECHANISMS OF CD4+ T CELL DYSFUNCTION IN SIV$327,916
R01 · FY2009 · AI · contact PI
Pilot Projects$181,104
U19 · FY2009 · AI · contact PI
DELIPIDATED LENTIVIRUSES TO IMPROVE PROTECTIVE RESPONSES POST SIV INFECTION$56,690
P51 · FY2009 · RR · contact PI
CD4 T CELL ACTIVATION IN SIV INFECTED DISEASE RESISTANT SOOTY MANGABEYS$56,690
P51 · FY2009 · RR · contact PI
ROLE OF VIRUS SPECIFIC IMMUNITY IN PRIMATE MODELS$56,690
P51 · FY2009 · RR · contact PI
EDUCATION COMPONENT$189,480
U19 · FY2008 · AI · contact PI
PILOT PROJECTS$189,476
U19 · FY2008 · AI · contact PI
ROLE OF VIRUS SPECIFIC IMMUNITY IN PRIMATE MODELS$67,958
P51 · FY2008 · RR · contact PI
CD4 T CELL ACTIVATION IN SIV INFECTED DISEASE RESISTANT SOOTY MANGABEYS$67,958
P51 · FY2008 · RR · contact PI
DELIPIDATED LENTIVIRUSES AS THERAPEUTIC IMMUNIZATION POST SIV INFECTION$67,958
P51 · FY2008 · RR · contact PI
EVALUATION OF DELIPIDATED LENTIVIRUSES AS MODE OF THERAPEUTIC IMMUNIZATION$67,958
P51 · FY2008 · RR · contact PI
DELIPIDATED LENTIVIRUSES AS THERAPEUTIC IMMUNIZATION POST SIV INFECTION$104,727
P51 · FY2007 · RR · contact PI
CD4 T CELL ACTIVATION IN SIV INFECTED DISEASE RESISTANT SOOTY MANGABEYS$91,637
P51 · FY2007 · RR · contact PI
ROLE OF VIRUS SPECIFIC IMMUNITY IN PRIMATE MODELS$91,635
P51 · FY2007 · RR · contact PI
Role of T Cell Immunity in Primate AIDS$467,827
R01 · FY2006 · AI · contact PI
LENTIVIRUSES AS IMMUNIZATION TO IMPROVE ANTIVIRAL RESPONSES POST SIV INFECTION$59,665
P51 · FY2006 · RR · contact PI
CD4 T CELL ACTIVATION IN SIV INFECTED DISEASE RESISTANT SOOTY MANGABEYS$59,665
P51 · FY2006 · RR · contact PI
ROLE OF VIRUS SPECIFIC IMMUNITY IN PRIMATE MODELS$59,665
P51 · FY2006 · RR · contact PI
Role of T Cell Immunity in Primate AIDS$450,295
R01 · FY2005 · AI
CD4T CELL ACTIVATION IN SIV INFECTED DISEASE RESISTANT SOOTY MANGABEYS$52,438
P51 · FY2005 · RR
EVALUATION OF PARTIAL DELIPIDATED LENTIVRUS AS MODE THERAPY$52,438
P51 · FY2005 · RR
ROLE OF VIRUS SPECIFIC IMMUNITY IN PRIMATE MODELS$52,438
P51 · FY2005 · RR
Role of T Cell Immunity in Primate AIDS$597,772
R01 · FY2004 · AI
CD4 T Cell Activation in SIV+Disease Resistant Mangabeys$266,000
R01 · FY2004 · AI
CD4 T CELL ACTIVATION IN SIV INFECTED SOOTY MANGABEYS$51,707
P51 · FY2004 · RR
ROLE OF VIRUS SPECIFIC IMMUNITY IN PRIMATE MODELS$51,707
P51 · FY2004 · RR
Role of T Cell Immunity in Primate AIDS$431,943
R01 · FY2003 · AI
HIV INFECTION/COCAINE EFFECT ON CARDIOVASCULAR PATHOLOGY$304,000
R01 · FY2003 · HL
CD4 T Cell Activation in SIV+Disease Resistant Mangabeys$266,000
R01 · FY2003 · AI
VIRUS SPECIFIC T CELL IMMUNITY IN PRIMATE AIDS: MECHANISMS OF AIDS PATHOGENESIS$85,297
P51 · FY2003 · RR
CO-STIMULATION OF MACAQUE CD4+ T CELLS RESISTANT TO SIV INFECTIONS$46,424
P51 · FY2003 · RR
CD4 T CELL ACTIVATION IN SIV INFECTED RESISTANT SOOTY MANGABEYS$46,424
P51 · FY2003 · RR
Role of T Cell Immunity in Primate AIDS$494,307
R01 · FY2002 · AI
HIV INFECTION/COCAINE EFFECT ON CARDIOVASCULAR PATHOLOGY$304,000
R01 · FY2002 · HL
CD4 T Cell Activation in SIV+Disease Resistant Mangabeys$260,280
R01 · FY2002 · AI
MACAQUE T CELLS CD3&28 PATHWAYS RESULTS IN EXPAN CD4+ TCELL RESISTANT TO SIV$209,143
P51 · FY2002 · RR
NOVEL NON NUCLEOSIDIC HIV REVERSE TRANSCRIPTASE INHIBITOR$209,143
P51 · FY2002 · RR
VIRUS SPECIFIC T CELL IMMUNITY PRIMATE AIDS$209,143
P51 · FY2002 · RR
VIRUS SPECIFIC T CELL IMMUNITY IN PRIMATE AIDS MECHANISMS OF AIDS PATHOGENESIS$209,143
P51 · FY2002 · RR
HIV INFECTION/COCAINE EFFECT ON CARDIOVASCULAR PATHOLOGY$38,000
R01 · FY2002 · HL
HIV INFECTION/COCAINE EFFECT ON CARDIOVASCULAR PATHOLOGY$304,333
R01 · FY2001 · HL
VIRUS SPECIFIC T CELL IMMUNITY AND PRIMATE AIDS$364,303
R01 · FY2000 · AI
HIV INFECTION/COCAINE EFFECT ON CARDIOVASCULAR PATHOLOGY$306,167
R01 · FY2000 · HL
VIRUS SPECIFIC T CELL IMMUNITY IN PRIMATE AIDS MECHANISMS OF AIDS PATHOGENESIS$84,459
P51 · FY2000 · RR
CD4+ T CELLS RESULTS IN EXPANSION OF CD4+ T CELLS RESISTANT TO SIV$84,459
P51 · FY2000 · RR
NOVEL NON NUCLEOSIDIC HIV REVERSE TRANSCRIPTASE INHIBITOR USING SHIV RT ISOLATE$84,458
P51 · FY2000 · RR
Interleukin 7 in inflammatory skin diseases$61,783
P30 · FY2000 · AR